Healthcare

The proposed head-to-head trial will recruit up to 80 young adults in the US with Major Depressive Disorder, comparing TRP-8803 against escitalopram, the most widely prescribed antidepressant in the US, with depression severity assessed over eight weeks and six months. The Company noted that …

On a statutory basis, revenue increased 1.8% to $3.7 billion, while statutory EBITDA fell 42.6% to $50.8 million and the Company recorded a statutory NPAT loss of $16.0 million, a decline of 177.9% compared with FY25. The statutory result includes an expense to recognise …

Revenue for the year to 30 June 2026 increased 9.9% to $13.5 billion, with Underlying EBITDA up 5.0% to $614 million. However, Underlying NPAT declined 3.1% to $250 million as depreciation, amortisation and financing costs rose following the group's infrastructure investment program. Underlying EPS …

The trial's primary endpoint compared treatment cost per percentage of total body surface area (TBSA) treated. PermeaDerm recorded a mean cost of $148.70 per 1% TBSA, against $497.10 for allograft — a saving of roughly $348 per percentage point and a 70% lower product …

Nanosonics Ltd trades on the exchange under the ticker NAN and operates within the healthcare space, spanning medical devices, diagnostics, care services and healthcare-technology providers. Investors researching NAN typically start with this sector context before layering in company-specific factors such asRevenuemix,Balance Sheetposition and competitive …

Regis Healthcare Ltd trades on the exchange under the ticker REG and operates within the healthcare space, spanning medical devices, diagnostics, care services and healthcare-technology providers. Investors researching REG typically start with this sector context before layering in company-specific factors such asRevenuemix,Balance Sheetposition and …

Chimeric Therapeutics Ltd trades on the exchange under the ticker CHM and operates within the healthcare space, spanning medical devices, diagnostics, care services and healthcare-technology providers. Investors researching CHM typically start with this sector context before layering in company-specific factors such asRevenuemix,Balance Sheetposition and …